TP53 and cancer: With overall 172 SCLC patients and 176 non-cancer controls, these works described in the plasma of patients the presence of a higher DNA concentration (with longer fragments), more frequent TP53 mutations (36% of patients with early-stage SCLCand 11% of non-cancer controls), detectable tumor-related mutations and CNAs by NGS in 84–94% of cases versus 0 in non-cancer controls, and detectable CTCs in 86% of cases versus 0% in healthy donors [10,11,23,24].